Study guide
4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors
Key Takeaways Explain This Topic AI
Local anesthetics reversibly block voltage-gated sodium channels by binding to the intracellular alpha-subunit in the uncharged base form (B) and physically obstructing sodium conductance in the charged conjugate acid form (BH+).
Amino amides (two 'i's: lidocaine, bupivacaine, ropivacaine, mepivacaine, prilocaine) undergo hepatic cytochrome P450 metabolism; amino esters (one 'i': cocaine, procaine, tetracaine, chloroprocaine) undergo plasma pseudocholinesterase hydrolysis into para-aminobenzoic acid (PABA), conferring higher allergic potential.
Physicochemical properties govern clinical action: pKa determines onset (pKa closest to pH 7.4 yields faster onset), lipid solubility determines potency (Meyer-Overton rule), and protein binding (to alpha-1 acid glycoprotein) determines duration of action.
Prilocaine and benzocaine metabolites oxidize ferrous iron (Fe2+) to ferric iron (Fe3+), causing methemoglobinemia characterized by cyanosis, dark chocolate-brown arterial blood, and a pulse oximeter fixed at ~85%; treated with Methylene Blue 1-2 mg/kg IV.
Local Anesthetic Systemic Toxicity (LAST) presents with progressive CNS excitation, seizures, CNS depression, and cardiovascular collapse; bupivacaine is exceptionally cardiotoxic (CC/CNS ratio 3.7) and is treated with 20% Lipid Emulsion (1.5 mL/kg bolus, 0.25-0.5 mL/kg/min infusion) while avoiding vasopressin and high-dose epinephrine.
Last updated: August 2026
4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors
Local anesthetics (LAs) reversibly prevent the generation and conduction of electrical impulses in excitable membranes (nerves, cardiac myocytes, skeletal muscle). They are fundamental to regional anesthesia, peripheral nerve blocks, neuraxial anesthesia, and multimodal pain pathways.
1. Molecular Mechanism of Action & State-Dependent Blockade
Local anesthetics inhibit nerve conduction by binding to a specific receptor site on the α \alpha α -subunit of voltage-gated sodium ( N a v Na_v N a v ) channels , physically occluding the channel pore from the inside and halting inward N a + Na^+ N a + current. Extracellular Fluid (pH 7.4) Lipid Bilayer (Axolemma) Intracellular Cytosol (pH 7.1)
- ───────────────────────────────────────────────────────────────────────────────────────────────────
- [BH+] ◄════► [B] + [H+] ───► [B] (Un-ionized Base) ───► [B] + [H+] ◄════► [BH+] (Cation)
- (Cannot Cross (Crosses Axolemma) │
- Membrane) ▼
- Binds Inner Na+ Pore
- (Blocks Na+ Influx)
- The Dual-Form Penetration and Binding Paradigm
Local anesthetics are weak bases with a tertiary amine group. In aqueous solution, they exist in equilibrium between an un-ionized, lipophilic free base form ( B B B ) and an ionized, hydrophilic conjugate acid cation ( B H + BH^+ B H + ) : B H + ⇌ B + H + where p H = p K a + log ( [ B ] [ B H + ] ) BH^+ \rightleftharpoons B + H^+ \quad \text{where} \quad pH = pKa + \log\left(\frac{[B]}{[BH^+]}\right) B H + ⇌ B + H + where p H = p K a + lo g ( [ B H + ] [ B ] )
Membrane Penetration: The un-ionized lipophilic base ( B B B ) readily diffuses across the hydrophobic phospholipid axolemma into the neuronal cytoplasm.
Channel Receptor Binding: Once intracellular, the base re-equilibrates into the ionized protonated cation ( B H + BH^+ B H + ) . The charged B H + BH^+ B H + molecule enters the open channel pore and binds with high affinity to the receptor site on the inner vestibule of the N a v Na_v N a v α \alpha α -subunit.
Use-Dependent (Phasic) vs. Tonic Blockade
Voltage-gated sodium channels cycle through three distinct conformational states: Resting (Closed) → \rightarrow → Active (Open) → \rightarrow → Inactive (Refractory) .
Local anesthetics exhibit use-dependent (phasic) block : they bind with significantly greater affinity to channels in the open (active) and inactivated (refractory) states than in the closed (resting) state.
Consequently, rapidly firing neurons (such as nociceptive pain fibers during surgical trauma, or rapid cardiac tachyarrhythmias) spend more time in open and inactivated states, accumulating local anesthetic molecules faster and exhibiting a deeper block than quiescent fibers.
Differential Nerve Fiber Sensitivity
Nerve fibers are classified based on diameter, myelination, and conduction velocity. Sensitivity to local anesthetic blockade follows a distinct hierarchy:
Fiber Type Myelination Diameter ( μ m \mu\text{m} μ m ) Function Relative Sensitivity to Local Anesthetic
B Fibers Lightly Myelinated 1 – 3 Preganglionic autonomic fibers Most Sensitive (Autonomic blockade occurs first)
A-Delta ( A δ A\delta A δ ) Lightly Myelinated 1 – 4 Sharp pain, temperature, touch High Sensitivity (Temperature/pinprick lost early)
A-Gamma ( A γ A\gamma A γ ) Myelinated 3 – 6 Muscle spindle tone High Sensitivity
C Fibers Unmyelinated 0.4 – 1.2 Dull aching pain, temperature, postganglionic autonomic Moderate Sensitivity (Slow conduction, easily blocked despite lack of myelin)
A-Beta ( A β A\beta A β ) Heavily Myelinated 5 – 12 Touch, pressure, proprioception Moderate-Low Sensitivity
A-Alpha ( A α A\alpha A α ) Heavily Myelinated 12 – 20 Motor function, proprioception Least Sensitive (Motor function is last to be blocked and first to recover)
Clinical Sequence of Differential Blockade: Autonomic (B fibers) → Temperature/Pain (A δ , C) → Touch/Pressure (A β ) → Motor (A α ) \text{Autonomic (B fibers)} \rightarrow \text{Temperature/Pain (A}\delta\text{, C)} \rightarrow \text{Touch/Pressure (A}\beta\text{)} \rightarrow \text{Motor (A}\alpha\text{)} Autonomic (B fibers) → Temperature/Pain (A δ , C) → Touch/Pressure (A β ) → Motor (A α )
2. Chemical Structure & Classification: Amino Esters vs. Amino Amides
All local anesthetic molecules share a fundamental three-part chemical architecture:
Lipophilic Aromatic Ring: Benzene derivative that determines lipid solubility, membrane penetration, and intrinsic anesthetic potency.
Intermediate Hydrocarbon Chain: Connects the aromatic ring to the amine group via either an Ester ( − C O O − -COO- − COO − ) or an Amide ( − N H − C O − -NH-CO- − N H − CO − ) bond. Dictates the metabolic pathway, duration, and allergic potential.
Hydrophilic Tertiary Amine: Weak base containing nitrogen that accepts hydrogen ions, dictating the p K a pKa p K a and degree of ionization at physiologic pH. [Lipophilic Aromatic Ring] ─────── [Intermediate Linkage: Ester or Amide] ─────── [Hydrophilic Tertiary Amine]
- (Potency & Lipid Partition) (Metabolic Fate & Allergy) (pKa & Ionization)
- The Spelling Rule for Identification
Amino Amides contain an "i" in the drug name prefix before the suffix "-caine":
L i docaine, Bup i vacaine, Rop i vacaine, Mep i vacaine, Pr i locaine, Levobup i vacaine, Art i caine (contains both an amide and a thiophene ester ring).
Amino Esters do NOT contain an "i" in the drug name prefix before the suffix "-caine":
Cocaine, Procaine, Tetracaine, Chloroprocaine, Benzocaine.
Pharmacologic Comparison: Esters vs. Amides
- Feature Amino Esters Amino Amides
- Chemical Bond Ester linkage ( − C O O − -COO- − COO − ) Amide linkage ( − N H − C O − -NH-CO- − N H − CO − )
Metabolic Site Plasma Pseudocholinesterase (Butyrylcholinesterase) via hydrolysis Hepatic Cytochrome P450 enzymes (CYP1A2, CYP3A4)
Rate of Metabolism Very Rapid (Chloroprocaine t 1 / 2 < 1 min t_{1/2} < 1\text{ min} t 1/2 < 1 min ; Tetracaine slower) Slower (Lidocaine t 1 / 2 ≈ 1.5 h t_{1/2} \approx 1.5\text{ h} t 1/2 ≈ 1.5 h ; Bupivacaine t 1 / 2 ≈ 3.5 h t_{1/2} \approx 3.5\text{ h} t 1/2 ≈ 3.5 h )
Major Metabolite Para-Aminobenzoic Acid (PABA) Inactive polar compounds (except prilocaine → \rightarrow → o -toluidine)
Allergic Potential Higher Allergic Potential (True IgE-mediated anaphylaxis to PABA metabolite) Extremely Rare Allergic Potential (<1%; reactions usually due to methylparaben preservative)
Stability in Solution Unstable; breaks down with heat/autoclaving and prolonged storage Highly stable; heat-stable, long shelf-life
Systemic Accumulation Minimal risk of accumulation High risk of accumulation with repeated dosing or liver disease
Loading diagram... Physicochemical Properties and Clinical Performance of Local Anesthetics
3. Physicochemical Determinants of Clinical Performance
Three physicochemical properties govern the clinical onset, potency, and duration of all local anesthetics:
1. p K a pKa p K a → \rightarrow → Speed of Onset
Definition: The p K a pKa p K a is the pH at which the drug is 50% un-ionized base ( B B B ) and 50% ionized cation ( B H + BH^+ B H + ) .
Mechanism: Because all local anesthetics have p K a pKa p K a values above 7.4 (ranging from 7.6 to 9.1), they exist predominantly as ionized cations ( B H + BH^+ B H + ) at physiologic pH. The closer the p K a pKa p K a is to physiologic pH (7.4), the higher the percentage of un-ionized lipophilic base ( B B B ) , allowing faster diffusion across the nerve sheath and resulting in a faster speed of onset .
The Acidosis/Infection Trap: In infected or inflamed tissue, local pH drops to 5.5–6.0. According to the Henderson-Hasselbalch equation, severe acidosis shifts the equilibrium overwhelmingly toward the charged B H + BH^+ B H + form ( > 99 % >99\% > 99% ionized), preventing the uncharged base from penetrating the axolemma and causing local anesthetic failure .
Sodium Bicarbonate Alkalinization: Adding 1 mL 1\text{ mL} 1 mL of 8.4 % N a H C O 3 8.4\%\ NaHCO_3 8.4% N a H C O 3 to 10 mL 10\text{ mL} 10 mL of 1 % or 2 % 1\%\text{ or } 2\% 1% or 2% lidocaine increases the solution pH, elevating the un-ionized base fraction ( B B B ). This accelerates onset of sensory block, deepens the block quality, and significantly reduces the stinging pain of injection.
2. Lipid Solubility → \rightarrow → Anesthetic Potency
Definition: Measured by the octanol:water partition coefficient.
Mechanism: Axolemmal membranes and myelin sheaths are 90% lipid. Highly lipid-soluble agents (Bupivacaine, Tetracaine, Ropivacaine) penetrate hydrophobic membranes with extreme ease, requiring a much smaller molar dose to achieve conduction block → \rightarrow → High Potency (formulated as 0.25% to 0.5% solutions). Low lipid-soluble agents (Procaine, Chloroprocaine, Mepivacaine, Lidocaine) require higher concentrations (1.0% to 3.0%).
3. Protein Binding → \rightarrow → Duration of Action
Definition: Percentage of drug bound to plasma and tissue proteins, primarily α 1 \alpha_1 α 1 -acid glycoprotein (AAG) (high affinity, low capacity) and albumin (low affinity, high capacity).
Mechanism: The degree of plasma protein binding directly mirrors the drug's binding affinity for protein receptor sites on the sodium channel. High protein binding creates a tissue depot at the receptor site, yielding a prolonged duration of action .
Summary Table of Physicochemical Constants & Dosing Limits
Local Anesthetic Agent Class p K a pKa p K a % Un-ionized at pH 7.4 Relative Potency Protein Binding Onset Speed Duration of Action Max Plain Dose (mg/kg) Max with Epi Dose (mg/kg)
Chloroprocaine (Nesacaine) Ester 8.7 ~5% 1 0% Fast (mass action) 30–60 min 11 mg/kg (800 mg) 14 mg/kg (1000 mg)
- Procaine (Novocain) Ester 8.9 ~3% 1 6% Slow 30–60 min 7 mg/kg (500 mg) 9 mg/kg (600 mg)
- Tetracaine (Pontocaine) Ester 8.5 ~7% 8 94% Slow 180–360 min 1.5 mg/kg (100 mg) 2.5 mg/kg (200 mg)
- Lidocaine (Xylocaine) Amide 7.9 25% 2 65% Fast 90–150 min 4.5 mg/kg (300 mg) 7.0 mg/kg (500 mg)
- Mepivacaine (Carbocaine) Amide 7.6 39% 2 77% Fastest 120–180 min 4.5 mg/kg (300 mg) 7.0 mg/kg (500 mg)
- Bupivacaine (Marcaine) Amide 8.1 17% 8 95% Moderate-Slow 240–480 min 2.5 mg/kg (175 mg) 3.0 mg/kg (225 mg)
- Ropivacaine (Naropin) Amide 8.1 17% 6 94% Moderate-Slow 240–480 min 3.0 mg/kg (200 mg) 3.5 mg/kg (250 mg)
- Prilocaine (Citanest) Amide 7.9 24% 2 55% Fast 90–180 min 6.0 mg/kg (400 mg) 8.0 mg/kg (600 mg)
- 4. Vasoconstrictor Additives & Tissue Absorption Kinetics
- Epinephrine Additive Dynamics (1:200,000 = 5 mcg/mL)
Co-administering epinephrine (1:200,000 or 5 μ g/mL 5\ \mu\text{g/mL} 5 μ g/mL ) with local anesthetics produces four major clinical effects:
Decreases Systemic Absorption: Stimulates local vascular α 1 \alpha_1 α 1 -adrenergic receptors, causing vasoconstriction that slows the rate of vascular uptake by 20% to 50%.
Reduces Peak Blood Levels ( C m a x C_{max} C ma x ): Flattens the plasma concentration curve, significantly diminishing the risk of Local Anesthetic Systemic Toxicity (LAST).
Prolongs Duration of Action: Keeps local anesthetic molecules localized around the nerve bundle for a longer duration (most pronounced for short- and intermediate-acting agents like lidocaine and mepivacaine; less pronounced for highly lipophilic agents like bupivacaine, which are already tightly bound to tissues).
Intravascular Injection Marker: Serves as a vital test dose marker ( 15 μ g 15\ \mu\text{g} 15 μ g epinephrine in 3 mL). Inadvertent intravascular injection triggers an acute heart rate increase ≥ 10 to 20 bpm \ge 10\text{ to } 20\text{ bpm} ≥ 10 to 20 bpm or systolic blood pressure rise ≥ 15 mmHg \ge 15\text{ mmHg} ≥ 15 mmHg within 30 to 60 seconds in non-beta-blocked patients.
Vascular Absorption Rates by Anatomical Block Site (ICEBS Mnemonic)
The peak systemic absorption rate and potential for toxicity depend directly on the vascularity of the injection site: I (Intravascular) > I (Intercostal) > C (Caudal) > E (Epidural) > B (Brachial Plexus) > S (Sciatic / Femoral) > S (Subcutaneous) \mathbf{I} \text{ (Intravascular)} > \mathbf{I} \text{ (Intercostal)} > \mathbf{C} \text{ (Caudal)} > \mathbf{E} \text{ (Epidural)} > \mathbf{B} \text{ (Brachial Plexus)} > \mathbf{S} \text{ (Sciatic / Femoral)} > \mathbf{S} \text{ (Subcutaneous)} I (Intravascular) > I (Intercostal) > C (Caudal) > E (Epidural) > B (Brachial Plexus) > S (Sciatic / Femoral) > S (Subcutaneous) I - B I C E P S : Intravenous > Intercostal > Caudal > Epidural > Brachial Plexus > Sciatic/Femoral > Subcutaneous \mathbf{I}\text{-}\mathbf{BICEPS:}\ \text{Intravenous } > \text{ Intercostal } > \text{ Caudal } > \text{ Epidural } > \text{ Brachial Plexus } > \text{ Sciatic/Femoral } > \text{ Subcutaneous} I - BICEPS : Intravenous > Intercostal > Caudal > Epidural > Brachial Plexus > Sciatic/Femoral > Subcutaneous
Intercostal nerve blocks yield the highest peak plasma drug concentrations ( C m a x C_{max} C ma x ) among all regional techniques due to the immense vascularity of the intercostal neurovascular bundle.
Subcutaneous infiltration exhibits the lowest vascular uptake and slowest absorption.
5. Drug-Induced Methemoglobinemia
Methemoglobinemia occurs when the normal ferrous iron ( F e 2 + Fe^{2+} F e 2 + ) within the heme moiety of hemoglobin is oxidized to the ferric state ( F e 3 + Fe^{3+} F e 3 + ) . Ferric heme cannot bind oxygen and causes an allosteric leftward shift of the oxyhemoglobin dissociation curve in remaining normal heme groups, severely impairing oxygen offloading to peripheral tissues. Normal Hemoglobin (Fe2+ Ferrous) ───[Oxidation by o-Toluidine / Benzocaine]───► Methemoglobin (Fe3+ Ferric)
- │
- ▼
- Pulse Oximeter Fixed at ~85% ◄─── Left Shift of Oxy-Hgb Curve ◄─── Incapable of Binding Oxygen
- Causative Anesthetic Agents
Prilocaine: Metabolized in the liver and lungs to ortho -toluidine , a potent oxidizing agent. Toxicity typically occurs at doses > 600 mg >600\text{ mg} > 600 mg ( > 8 mg/kg >8\text{ mg/kg} > 8 mg/kg ).
Benzocaine: High-concentration topical sprays (e.g., Hurricaine spray 20% , Cetacaine) used for awake fiberoptic intubation, endoscopy, or TEE probe placement. Even short 1- to 2-second sprays can precipitate fulminant methemoglobinemia.
EMLA Cream: Eutectic Mixture of Local Anesthetics (2.5% Lidocaine + 2.5% Prilocaine); excessive topical application in neonates and infants with immature methemoglobin reductase pathways.
Clinical Presentation & Diagnostics
Symptoms: Grayish-blue cyanosis refractory to 100% inspired oxygen, fatigue, headache, tachypnea, metabolic lactic acidosis, altered mental status, and syncope.
Physical Exam: Arterial blood drawn displays a distinct, non-clotting dark chocolate-brown color that does not turn bright red when exposed to atmospheric air.
Pulse Oximetry Artefact: The standard pulse oximeter ( S p O 2 SpO_2 Sp O 2 ) reads falsely fixed at approximately 85% , regardless of the true arterial oxygenation. This occurs because methemoglobin absorbs both 660 nm (red) and 940 nm (infrared) wavelengths equally (1:1 absorbance ratio), which the oximeter microprocessor interprets as an S p O 2 SpO_2 Sp O 2 of 85%.
Gold Standard Diagnosis: Co-oximetry blood gas analysis , which measures the exact percentage of methemoglobin (MetHb > 15–20% causes symptomatic cyanosis; MetHb > 50–70% is lethal).
Definitive Management: Methylene Blue Protocol Methylene Blue Dose: 1.0 to 2.0 mg/kg IV over 5 minutes \text{Methylene Blue Dose: } \mathbf{1.0\text{ to } 2.0\text{ mg/kg IV}} \text{ over 5 minutes} Methylene Blue Dose: 1.0 to 2.0 mg/kg IV over 5 minutes
Mechanism: Methylene blue acts as an exogenous electron acceptor cofactor for NADPH-methemoglobin reductase , accelerating the enzymatic reduction of ferric iron ( F e 3 + Fe^{3+} F e 3 + ) back to ferrous iron ( F e 2 + Fe^{2+} F e 2 + ).
Contraindications & Warnings:
Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: Patients lack NADPH generated by the hexose monophosphate shunt. Administering methylene blue is ineffective and triggers severe acute hemolytic anemia . Treatment in G6PD: Ascorbic acid (Vitamin C 300–500 mg/day) and hyperbaric oxygen.
Serotonergic Antidepressants (SSRIs / SNRIs / MAOIs): Methylene blue is a potent monoamine oxidase-A (MAO-A) inhibitor; co-administration can precipitate life-threatening Serotonin Syndrome .
Loading diagram... ASRA Checklist for the Management of Local Anesthetic Systemic Toxicity (LAST)
6. Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue
Local Anesthetic Systemic Toxicity (LAST) is a life-threatening complication resulting from accidental intravascular injection or massive systemic absorption of local anesthetics.
Clinical Progression of LAST
Because the central nervous system is more sensitive to local anesthetic toxicity than the cardiovascular system, CNS signs classically precede cardiovascular collapse:
Early CNS Excitation (Subjective / Cortical): Circumoral paresthesias, tongue numbness, metallic taste, tinnitus, lightheadedness, visual disturbances, and slurred speech.
Advanced CNS Excitation (Motor / Subcortical): Shivering, involuntary muscle twitching, facial tremors, and generalized tonic-clonic grand mal seizures (caused by selective blockade of inhibitory cortical interneurons, leaving unopposed excitatory NMDA pathways).
CNS Depression: Global CNS depression, loss of consciousness, coma, and central apnea.
Cardiovascular Toxicity: Biphasic response. Initial transient sympathetic surge (hypertension, tachycardia), followed rapidly by profound myocardial depression, peripheral vasodilation, conduction delays (prolonged PR, widened QRS), sinus bradycardia, ventricular dysrhythmias ( Torsades de pointes, ventricular fibrillation ), and asystole.
Bupivacaine Cardiotoxicity vs. Lidocaine ( C C / C N S CC/CNS CC / CNS Ratio)
The CC/CNS Ratio: The ratio of the drug dose required to produce C ardiovascular C ollapse compared to the dose required to produce CNS seizures ( C C / C N S CC/CNS CC / CNS ratio).
Lidocaine: C C / C N S ratio = 7.1 CC/CNS\text{ ratio} = \mathbf{7.1} CC / CNS ratio = 7.1 . Lidocaine provides a broad safety margin; severe CNS toxicity and seizures appear well before cardiovascular toxicity manifests.
Bupivacaine: C C / C N S ratio = 3.7 CC/CNS\text{ ratio} = \mathbf{3.7} CC / CNS ratio = 3.7 . Bupivacaine has a very narrow margin of safety; fatal cardiac arrhythmias can occur almost simultaneously with seizures.
The "Fast In, Slow Out" Kinetic Trap: Bupivacaine binds rapidly to open and inactivated cardiac N a v 1.5 Na_v1.5 N a v 1.5 sodium channels during ventricular systole ("fast in"), but dissociates from resting channels during diastole extremely slowly ("slow out", t 1 / 2 > 150 s t_{1/2} > 150\text{ s} t 1/2 > 150 s compared to < 0.2 s <0.2\text{ s} < 0.2 s for lidocaine). Bupivacaine accumulates on cardiac channels at normal heart rates, generating profound conduction blocks, re-entrant ventricular fibrillation, and electromechanical dissociation.
S − ( − ) S-(-) S − ( − ) Enantiomers (Ropivacaine & Levobupivacaine): Formulated as pure single enantiomers. The S S S -isomer has significantly lower affinity for cardiac sodium channels than the R − ( + ) R-(+) R − ( + ) isomer of racemic bupivacaine, providing a wider safety margin and higher C C / C N S CC/CNS CC / CNS ratio.
- ASRA LAST Treatment Protocol & 20% Lipid Emulsion Guidelines
- Immediate Actions & Supportive Care
Stop Injection Immediately: Discontinue local anesthetic administration at the first sign of toxicity.
Call for Help & Retrieve LAST Rescue Kit: Request the local anesthetic rescue cart and 20% Lipid Emulsion (Intralipid) immediately. Alert the nearest cardiopulmonary bypass / ECMO team.
Airway & Ventilation: Ventilate with 100% O 2 O_2 O 2 . Hyperventilate mildly to prevent hypoxia, hypercapnia ( P a C O 2 ↑ PaCO_2 \uparrow P a C O 2 ↑ ), and acidosis ( p H ↓ pH \downarrow p H ↓ ) , all of which exacerbate LAST by increasing cerebral blood flow (delivering more local anesthetic to the brain), displacing local anesthetic from plasma proteins, and reducing the seizure threshold.
Seizure Control: Administer Midazolam (1 to 2 mg IV) or other benzodiazepines. Avoid large doses of propofol, which further depress myocardial contractility.
Critical ACLS Resuscitation Modifications
Reduce Epinephrine Doses: Use small initial doses of Epinephrine < 1 μ g/kg <1\ \mu\text{g/kg} < 1 μ g/kg (e.g., 10 to 100 mcg boluses in adults). Standard large ACLS doses (1 mg) worsen lipid resuscitation, impair myocardial microvascular perfusion, and trigger severe ventricular arrhythmias.
AVOID Vasopressin: Strictly contraindicated; vasopressin worsens pulmonary edema, increases afterload, and impairs resuscitation outcomes.
AVOID Calcium Channel Blockers and β \beta β -Blockers: Exacerbate myocardial depression and heart block.
AVOID Local Anesthetic Antiarrhythmics (Lidocaine, Procainamide): Lidocaine adds to the systemic local anesthetic burden.
Amiodarone is the antiarrhythmic of choice for ventricular dysrhythmias.
20% Lipid Emulsion Dosing Protocol (Actual Body Weight) I n i t i a l B o l u s : 1.5 mL/kg IV over 2 to 3 minutes ( ≈ 100 mL for a 70 kg adult ) C o n t i n u o u s I n f u s i o n : 0.25 mL/kg/min IV ( ≈ 18 mL/min or 1000 mL/hr for 70 kg ) R e − b o l u s C r i t e r i a : If cardiovascular instability persists, repeat 1.5 mL/kg bolus once or twice every 3–5 minutes and double infusion rate to 0.5 mL/kg/min M a x i m u m T o t a l D o s e : 12 mL/kg IV over the first 30 minutes \begin{aligned}
\mathbf{Initial\ Bolus:} & \quad \mathbf{1.5\text{ mL/kg IV}} \text{ over 2 to 3 minutes } (\approx 100\text{ mL for a } 70\text{ kg adult}) \\[4pt]
\mathbf{Continuous\ Infusion:} & \quad \mathbf{0.25\text{ mL/kg/min IV}} (\approx 18\text{ mL/min or } 1000\text{ mL/hr for } 70\text{ kg}) \\[4pt]
\mathbf{Re-bolus\ Criteria:} & \quad \text{If cardiovascular instability persists, repeat } 1.5\text{ mL/kg bolus once or twice} \\[2pt]
- & \quad \text{every 3–5 minutes and double infusion rate to } \mathbf{0.5\text{ mL/kg/min}} \\[4pt]
- \mathbf{Maximum\ Total\ Dose:} & \quad \mathbf{12\text{ mL/kg IV}} \text{ over the first 30 minutes}
\end{aligned} Initial Bolus : Continuous Infusion : Re − bolus Criteria : Maximum Total Dose : 1.5 mL/kg IV over 2 to 3 minutes ( ≈ 100 mL for a 70 kg adult ) 0.25 mL/kg/min IV ( ≈ 18 mL/min or 1000 mL/hr for 70 kg ) If cardiovascular instability persists, repeat 1.5 mL/kg bolus once or twice every 3–5 minutes and double infusion rate to 0.5 mL/kg/min 12 mL/kg IV over the first 30 minutes
Mechanisms of Lipid Emulsion Therapy:
Lipid Sink Theory: Acts as an intravascular lipid compartment that extracts lipophilic local anesthetic molecules from highly perfused target tissues (heart and brain).
Metabolic Activation: Overcomes local anesthetic-induced inhibition of mitochondrial carnitine acyltransferase, providing fatty acid substrates for myocardial ATP production.
Direct Positive Inotropic & Membrane Effects: Restores intracellular calcium handling and reverses cardiac sodium channel blockade.